Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Nutra Pharma Announces Orphan Drug Applications for RPI-78M

Nutra Pharma Has Announced That They Have Engaged Medical strategy Consultants LLC to Aid in the Creation and Filing of Orphan Drug Applications With the US Food and Drug Administration CORAL SPRINGS, FL–(Marketwired – May 26, 2015) – Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human […]

Read More »

Bavarian Nordic not for sale after big pharma deals

Bavarian Nordic is hot property after striking two big vaccine deals but the small Danish company is not for sale, despite a wave of consolidation in the healthcare industry, its chief told Reuters.       Best known before for selling smallpox vaccine to governments worried about biosecurity, Bavarian’s share price has tripled after signing deals […]

Read More »

Retrophin Banks $245 Million From Sanofi for Priority Review Voucher

SAN DIEGO, May 27, 2015 (BUSINESS WIRE) — Retrophin, Inc. RTRX, +9.56% today announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher (“Pediatric PRV”) to Sanofi SNY, +1.08% Retrophin received the Pediatric PRV when Cholbam™ was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric and adult […]

Read More »

The Most Powerful Women In Science And Health

Power can come from all kinds of industries and sectors, from politics and investing to media and even fashion. But one thing all the women on FORBES’ 12th list of 100 Most Powerful Women have in common is brainpower. Seven of those brainy women have roots in science and health, although they work in a […]

Read More »

Betting On Cancer Treatment? Keep An Eye On This Company

NeoStem Inc recently received a grant of $17.7 million to fund the company’s effort in research of cell therapy products for cancer from California Institute of Regenerative Medicine. Following the announcement of the grant, shares of NeoStem rose by over 20 percent. NeoStem CEO Dr. David Mazzo was on Fox Business News recently to talk […]

Read More »

AstraZeneca hit after psoriasis drug linked to suicide fears

AstraZeneca’s (AZN.L) hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller.    Amgen (AMGN.O), its partner on the project, announced late on Friday it was ending a collaboration to develop brodalumab […]

Read More »

Another Top Sanofi Exec Resigns, As Purging of Old Guard Continues

The purging of the old guard installed by former chief exec Chris Viehbacher continued at French drugmaker Sanofi (SNY) Monday, when the firm’s global head for prostate cancer drug Jevtana, Zhen Su, left to find work outside the company. The company did not issue a release on Su’s departure but the press learned about it […]

Read More »

GlaxoSmithKline Shareholders Are Willing to Give CEO Time to Revive Company: Report

Despite sagging stock prices, major investors in U.K.-based GlaxoSmithKline (GSK) indicated yesterday they are willing to give company CEO Andrew Witty time to turn the company’s fortunes around—but probably not too much time. GSK did not respond to a request for a statement in time for deadline. The Financial Times reported that shareholders have decided […]

Read More »

Amgen Dumps AstraZeneca PLC Pact After Patients Developed Suicidal Thoughts

THOUSAND OAKS, Calif., May 22, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the Company has commenced termination of its participation in the co-development and commercialization of brodalumab with AstraZeneca (LON:AZN, STO:AZN and NYSE:AZN). Brodalumab, an investigational IL-17 inhibitor, is in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The decision was […]

Read More »

How Pricey Specialty Drugs Spurred CVS’ Omnicare Deal

When drugs cost $1,000 a pill or $25,000 for a year of injections, insurers and employers want to make sure these prescriptions are being taken at the right place and at the right time and have the right outcome for the patient. After all, trends in insurance payment from private insurers as well as government […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom